Study Summary
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Want to learn more about this trial?
Request More InfoInterventions
UCART123v1.2BIOLOGICAL
Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center | San Francisco | California | United States |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | United States |
| Northwestern University | Chicago | Illinois | United States |
| Dana-Farber Cancer Institute | Boston | Massachusetts | United States |
| Roswell Park Cancer Institute | Buffalo | New York | United States |
| Weill Medical College of Cornell University | New York | New York | United States |
| University of Pennsylvania - Abramson Cancer Center | Philadelphia | Pennsylvania | United States |
| MD Anderson Cancer Center | Houston | Texas | United States |